Buchumschlag

Cachexia in patients with chronic pancreatitis and pancreatic cancer: impact on survival and outcome

Chronic pancreatitis (CP) and pancreatic adenocarcinoma (PDAC) are the most common diseases of the pancreas. Cachexia—weight loss exceeding 10% of stable body weight—is present in up to 80% of patients with PDAC. Because the mechanisms of cachexia are not well known, this provides a possibility to c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bachmann, Jeannine (VerfasserIn) , Büchler, Markus W. (VerfasserIn) , Friess, Helmut (VerfasserIn) , Martignoni, Marc E. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 02 Aug 2013
In: Nutrition and cancer
Year: 2013, Jahrgang: 65, Heft: 6, Pages: 827-833
ISSN:1532-7914
DOI:10.1080/01635581.2013.804580
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/01635581.2013.804580
Volltext
Verfasserangaben:Jeannine Bachmann, Markus W. Büchler, Helmut Friess & Marc E. Martignoni
Beschreibung
Zusammenfassung:Chronic pancreatitis (CP) and pancreatic adenocarcinoma (PDAC) are the most common diseases of the pancreas. Cachexia—weight loss exceeding 10% of stable body weight—is present in up to 80% of patients with PDAC. Because the mechanisms of cachexia are not well known, this provides a possibility to compare clinical courses of benign and malignant cachexia. In this study, 382 patients—242 with a PDAC stage UICC II/ 140 with CP—were documented regarding the prevalence of cachexia and its influence on perioperative morbidity and mortality with a special interest to postoperative weight gain and survival. Cachexia was present in 41.4% of CP and 31% of cancer patients. We could demonstrate more pronounced systemic effects of cachexia in patients with PDAC. Weight loss was faster in PDAC patients, the amount of weight loss did not differ significantly between the groups. Cachexia had a significant impact on survival and the postoperative course in patients with PDAC and tumor resection. The development of cachexia is faster in patients with a malignant disease and the systemic effects are more pronounced. Therefore, tumor cachexia should be considered as a different entity than cachexia in benign diseases.
Beschreibung:Gesehen am 30.10.2020
Beschreibung:Online Resource
ISSN:1532-7914
DOI:10.1080/01635581.2013.804580

Ähnliche Einträge